AUTOLUS THERAPEUTICS PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.19 USD | +5.01% |
|
+6.89% | -34.94% |
Financials (USD)
| Sales 2024 * | 20.34M | Sales 2025 * | 71.52M | Capitalization | 1.11B |
|---|---|---|---|---|---|
| Net income 2024 * | -198M | Net income 2025 * | -138M | EV / Sales 2024 * | 23.9 x |
| Net cash position 2024 * | 629M | Net cash position 2025 * | 542M | EV / Sales 2025 * | 8.01 x |
| P/E ratio 2024 * |
-4.88
x | P/E ratio 2025 * |
-7.6
x | Employees | 467 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 3.32% |
More Fundamentals
* Assessed data
More news
Latest transcript on Autolus Therapeutics plc
More recommendations
More press releases
| 1 day | +5.01% | ||
| 1 week | +6.89% | ||
| 1 month | +13.86% | ||
| 3 months | -30.17% | ||
| 6 months | -2.10% | ||
| Current year | -34.94% |
1 week
3.90
4.21
1 month
3.754.84
Current year
3.617.45
1 year
2.017.45
3 years
1.608.23
5 years
1.6020.85
10 years
1.6053.24
| Managers | Title | Age | Since |
|---|---|---|---|
Martin Pulé
FOU | Founder | 51 | 14-08-31 |
Christian Itin
CEO | Chief Executive Officer | 59 | 14-09-30 |
Robert Dolski
DFI | Director of Finance/CFO | 54 | 23-08-06 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
John Berriman
BRD | Director/Board Member | 76 | 14-07-31 |
William Young
BRD | Director/Board Member | 79 | 21-11-14 |
Cynthia Butitta
BRD | Director/Board Member | 69 | 18-02-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.05% | 2 M€ | -.--% | ||
| 0.01% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-31 | 4.19 | +5.01% | 1,494,830 |
| 24-05-30 | 3.99 | -0.75% | 885,826 |
| 24-05-29 | 4.02 | -.--% | 638,508 |
| 24-05-28 | 4.02 | +2.55% | 529,920 |
| 24-05-24 | 3.92 | +1.29% | 511,867 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm EDT
More quotes
Autolus Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. It is focused on chimeric antigen receptor (CAR)-T cell therapy. Using a suite of proprietary and modular T cell programming technologies, it is engineering targeted, controlled and highly active T cell therapy product candidates that are designed to recognize target cells, break down their defense mechanisms and eliminate these cells. It has a pipeline of product candidates in development for the treatment of hematological malignancies, solid tumors and autoimmune diseases. Its products pipeline includes obe-cel (FELIX), obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting T Cell Receptor Beta Constant (TRBC) 1 and TRBC 2.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
4.19
USD
Average target price
10.54
USD
Spread / Average Target
+151.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -34.94% | 1.11B | |
| +11.91% | 118B | |
| +11.60% | 106B | |
| -4.68% | 24.28B | |
| -0.82% | 21.96B | |
| -10.12% | 18.16B | |
| -42.12% | 16.37B | |
| -17.47% | 15.56B | |
| +2.77% | 13.63B | |
| +34.58% | 12.27B |
- Stock Market
- Equities
- AUTL Stock
